JP2008524249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524249A5 JP2008524249A5 JP2007546990A JP2007546990A JP2008524249A5 JP 2008524249 A5 JP2008524249 A5 JP 2008524249A5 JP 2007546990 A JP2007546990 A JP 2007546990A JP 2007546990 A JP2007546990 A JP 2007546990A JP 2008524249 A5 JP2008524249 A5 JP 2008524249A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- amide
- carboxylic acid
- benzoxazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- -1 C 1 -C 4 alkyl Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 2
- GIBVENMRXKZTPM-UHFFFAOYSA-N 2-n-methyl-2-n-(1-methylpiperidin-4-yl)-1,3-benzoxazole-2,5-diamine Chemical compound N=1C2=CC(N)=CC=C2OC=1N(C)C1CCN(C)CC1 GIBVENMRXKZTPM-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- ZOUCZKGFQSOBPX-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-[2-[methyl-[(1-methylpyrrolidin-3-yl)methyl]amino]-1,3-benzothiazol-6-yl]prop-2-enamide Chemical compound N=1C2=CC=C(NC(=O)C=CC=3C=CC(F)=CC=3)C=C2SC=1N(C)CC1CCN(C)C1 ZOUCZKGFQSOBPX-UHFFFAOYSA-N 0.000 claims 1
- YEVSVQXTBWMTFO-UHFFFAOYSA-N 4-(2,3-dichlorophenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=CC(Cl)=C1Cl YEVSVQXTBWMTFO-UHFFFAOYSA-N 0.000 claims 1
- ONBXLEVZJQBTIT-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1Cl ONBXLEVZJQBTIT-UHFFFAOYSA-N 0.000 claims 1
- MYCDLACXMUBSAJ-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]benzamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1Cl MYCDLACXMUBSAJ-UHFFFAOYSA-N 0.000 claims 1
- STUCRICXTMRQCU-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-n-[2-[methyl-[(1-methylpyrrolidin-3-yl)methyl]amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C(=CC(Cl)=CC=3)Cl)=CC=C2OC=1N(C)CC1CCN(C)C1 STUCRICXTMRQCU-UHFFFAOYSA-N 0.000 claims 1
- OZFFPJBMCGKDGO-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(Cl)C=C1Cl OZFFPJBMCGKDGO-UHFFFAOYSA-N 0.000 claims 1
- LHKWCYAXJCSSSD-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(F)C=C1F LHKWCYAXJCSSSD-UHFFFAOYSA-N 0.000 claims 1
- SUFQYLDLNPIWFA-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C(=CC(F)=CC=3)F)=CC=C2OC=1N(C)C1CCN(C)CC1 SUFQYLDLNPIWFA-UHFFFAOYSA-N 0.000 claims 1
- FCTRGPBVBWWFEO-UHFFFAOYSA-N 4-(2-chloro-4-fluorophenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(F)C=C1Cl FCTRGPBVBWWFEO-UHFFFAOYSA-N 0.000 claims 1
- ZFEFJGBXOJPMJV-UHFFFAOYSA-N 4-(2-chloro-4-fluorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C(=CC(F)=CC=3)Cl)=CC=C2OC=1N(C)C1CCN(C)CC1 ZFEFJGBXOJPMJV-UHFFFAOYSA-N 0.000 claims 1
- GEYIMGZCBBHLLS-UHFFFAOYSA-N 4-(2-chloro-4-methoxyphenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound ClC1=CC(OC)=CC=C1C1=CC=C(C(=O)NC=2C=C3SC(=NC3=CC=2)N(C)CCN(C)C)C=C1 GEYIMGZCBBHLLS-UHFFFAOYSA-N 0.000 claims 1
- VPVLGKHWGDSWOS-UHFFFAOYSA-N 4-(2-chloro-4-methoxyphenyl)-n-[2-[methyl-(1-methylpyrrolidin-3-yl)amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound ClC1=CC(OC)=CC=C1C1=CC=C(C(=O)NC=2C=C3SC(=NC3=CC=2)N(C)C2CN(C)CC2)C=C1 VPVLGKHWGDSWOS-UHFFFAOYSA-N 0.000 claims 1
- JUGMJUMMUIXDDH-UHFFFAOYSA-N 4-(2-chloro-4-methylphenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(C)C=C1Cl JUGMJUMMUIXDDH-UHFFFAOYSA-N 0.000 claims 1
- SABVGGGSSMUCHU-UHFFFAOYSA-N 4-(2-chloro-4-methylphenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]benzamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=C(C)C=C1Cl SABVGGGSSMUCHU-UHFFFAOYSA-N 0.000 claims 1
- IMJSHZCHEKCMMO-UHFFFAOYSA-N 4-(2-chloro-4-methylphenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C(=CC(C)=CC=3)Cl)=CC=C2OC=1N(C)C1CCN(C)CC1 IMJSHZCHEKCMMO-UHFFFAOYSA-N 0.000 claims 1
- KLFMHWMYKHXPPX-UHFFFAOYSA-N 4-(2-chlorophenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1Cl KLFMHWMYKHXPPX-UHFFFAOYSA-N 0.000 claims 1
- LZYQNYCOIAILLB-UHFFFAOYSA-N 4-(4-chloro-2-methylphenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1C LZYQNYCOIAILLB-UHFFFAOYSA-N 0.000 claims 1
- ZNIIXHHZSKDKNX-UHFFFAOYSA-N 4-(4-chloro-2-methylphenyl)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]benzamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1C ZNIIXHHZSKDKNX-UHFFFAOYSA-N 0.000 claims 1
- ZPWCHBUCSRAAJV-UHFFFAOYSA-N 4-(4-chloro-2-methylphenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C(=CC(Cl)=CC=3)C)=CC=C2OC=1N(C)C1CCN(C)CC1 ZPWCHBUCSRAAJV-UHFFFAOYSA-N 0.000 claims 1
- RJPXKIYFULVOOL-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl(2-morpholin-4-ylethyl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)CCN1CCOCC1 RJPXKIYFULVOOL-UHFFFAOYSA-N 0.000 claims 1
- UVZCNFSHRBNSIZ-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl(2-piperidin-1-ylethyl)amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound N=1C2=CC=C(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)C=C2SC=1N(C)CCN1CCCCC1 UVZCNFSHRBNSIZ-UHFFFAOYSA-N 0.000 claims 1
- RIACNWLBDGUXRR-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound N=1C2=CC=C(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)C=C2SC=1N(C)CCN1CCCC1 RIACNWLBDGUXRR-UHFFFAOYSA-N 0.000 claims 1
- DTUTWRXCWDQXLW-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl(2-pyrrolidin-1-ylethyl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)CCN1CCCC1 DTUTWRXCWDQXLW-UHFFFAOYSA-N 0.000 claims 1
- DENUYBFZOWWZMD-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl(pyrrolidin-3-ylmethyl)amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound N=1C2=CC=C(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)C=C2SC=1N(C)CC1CCNC1 DENUYBFZOWWZMD-UHFFFAOYSA-N 0.000 claims 1
- ZVUJSQKAGDBYOW-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl-(1-methylpiperidin-3-yl)amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound N=1C2=CC=C(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)C=C2SC=1N(C)C1CCCN(C)C1 ZVUJSQKAGDBYOW-UHFFFAOYSA-N 0.000 claims 1
- UYMHAJRALJBIPW-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl-(1-methylpiperidin-3-yl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)C1CCCN(C)C1 UYMHAJRALJBIPW-UHFFFAOYSA-N 0.000 claims 1
- IZDIJERBVRWNHB-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound N=1C2=CC=C(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)C=C2SC=1N(C)C1CCN(C)CC1 IZDIJERBVRWNHB-UHFFFAOYSA-N 0.000 claims 1
- ZKZAICOOMBXCAD-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 ZKZAICOOMBXCAD-UHFFFAOYSA-N 0.000 claims 1
- PFEVGHCXMYFBMG-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl-(1-methylpyrrolidin-3-yl)amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound N=1C2=CC=C(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)C=C2SC=1N(C)C1CCN(C)C1 PFEVGHCXMYFBMG-UHFFFAOYSA-N 0.000 claims 1
- AEFQFYCFMSYGIW-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl-[(1-methylpyrrolidin-3-yl)methyl]amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound N=1C2=CC=C(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)C=C2SC=1N(C)CC1CCN(C)C1 AEFQFYCFMSYGIW-UHFFFAOYSA-N 0.000 claims 1
- HZXNSRKYOLVDLC-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl-[(1-methylpyrrolidin-3-yl)methyl]amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)CC1CCN(C)C1 HZXNSRKYOLVDLC-UHFFFAOYSA-N 0.000 claims 1
- HYBZZXNHVCSXTD-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl-[(1-propan-2-ylpyrrolidin-3-yl)methyl]amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1N(C(C)C)CCC1CN(C)C(SC1=C2)=NC1=CC=C2NC(=O)C1=CC=C(C=2C=CC(F)=CC=2)C=C1 HYBZZXNHVCSXTD-UHFFFAOYSA-N 0.000 claims 1
- YCMLBMBFGGTDJG-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[2-[methyl-[(4-methylmorpholin-2-yl)methyl]amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)CC1CN(C)CCO1 YCMLBMBFGGTDJG-UHFFFAOYSA-N 0.000 claims 1
- ZOXJDUXHJQLQSQ-UHFFFAOYSA-N 4-(cyclohexylmethoxy)-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]benzamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1OCC1CCCCC1 ZOXJDUXHJQLQSQ-UHFFFAOYSA-N 0.000 claims 1
- PVZKHGCZCWBUFT-UHFFFAOYSA-N 4-(cyclohexylmethoxy)-n-[2-[methyl-(1-methylpyrrolidin-3-yl)amino]-1,3-benzothiazol-6-yl]benzamide Chemical compound N=1C2=CC=C(NC(=O)C=3C=CC(OCC4CCCCC4)=CC=3)C=C2SC=1N(C)C1CCN(C)C1 PVZKHGCZCWBUFT-UHFFFAOYSA-N 0.000 claims 1
- YXKFVWASWPAUPW-UHFFFAOYSA-N 4-[2-chloro-4-(trifluoromethoxy)phenyl]-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(OC(F)(F)F)C=C1Cl YXKFVWASWPAUPW-UHFFFAOYSA-N 0.000 claims 1
- NKIOIHGLSSJCCL-UHFFFAOYSA-N 4-[2-chloro-4-(trifluoromethyl)phenyl]-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1Cl NKIOIHGLSSJCCL-UHFFFAOYSA-N 0.000 claims 1
- LSRPRFQIHPWLLJ-UHFFFAOYSA-N 4-butyl-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]benzamide Chemical compound C1=CC(CCCC)=CC=C1C(=O)NC1=CC=C(OC(=N2)N(C)CCN(C)C)C2=C1 LSRPRFQIHPWLLJ-UHFFFAOYSA-N 0.000 claims 1
- IOZTWPVHQPXZIB-UHFFFAOYSA-N 4-butyl-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound C1=CC(CCCC)=CC=C1C(=O)NC1=CC=C(OC(=N2)N(C)C3CCN(C)CC3)C2=C1 IOZTWPVHQPXZIB-UHFFFAOYSA-N 0.000 claims 1
- ZHXWJURUCGVVNP-UHFFFAOYSA-N 4-cyclohexyl-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1CCCCC1 ZHXWJURUCGVVNP-UHFFFAOYSA-N 0.000 claims 1
- RBUXIZRDHUTKLX-UHFFFAOYSA-N 4-cyclohexyl-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]benzamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1C1CCCCC1 RBUXIZRDHUTKLX-UHFFFAOYSA-N 0.000 claims 1
- MHLZYUDQMAURHU-UHFFFAOYSA-N 4-cyclohexyl-n-[2-[3-(dimethylamino)propyl-methylamino]-1,3-benzoxazol-5-yl]benzamide Chemical compound C=1C=C2OC(N(C)CCCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1C1CCCCC1 MHLZYUDQMAURHU-UHFFFAOYSA-N 0.000 claims 1
- GQSGWVSFLDDCQL-UHFFFAOYSA-N 4-cyclohexyl-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C3CCCCC3)=CC=C2OC=1N(C)C1CCN(C)CC1 GQSGWVSFLDDCQL-UHFFFAOYSA-N 0.000 claims 1
- FQSXZROVGPLTIC-UHFFFAOYSA-N 4-cyclohexyl-n-[2-[methyl-[(1-methylpyrrolidin-3-yl)methyl]amino]-1,3-benzoxazol-5-yl]benzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C3CCCCC3)=CC=C2OC=1N(C)CC1CCN(C)C1 FQSXZROVGPLTIC-UHFFFAOYSA-N 0.000 claims 1
- HQVFLHIVNFRORQ-UHFFFAOYSA-N 4-cyclohexyloxy-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1OC1CCCCC1 HQVFLHIVNFRORQ-UHFFFAOYSA-N 0.000 claims 1
- GYQUEDMRCRSIFG-UHFFFAOYSA-N 4-cyclohexyloxy-n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]benzamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1OC1CCCCC1 GYQUEDMRCRSIFG-UHFFFAOYSA-N 0.000 claims 1
- SVFIPJLEPHBEDN-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]thiophene-2-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3SC(=CC=3)C=3C=C4OCOC4=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 SVFIPJLEPHBEDN-UHFFFAOYSA-N 0.000 claims 1
- RQFTVLJJTFOTGR-UHFFFAOYSA-N 5-(2,4-difluorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]thiophene-2-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3SC(=CC=3)C=3C(=CC(F)=CC=3)F)=CC=C2OC=1N(C)C1CCN(C)CC1 RQFTVLJJTFOTGR-UHFFFAOYSA-N 0.000 claims 1
- NBXILYIJACTNDG-UHFFFAOYSA-N 5-(3,4-difluorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]thiophene-2-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3SC(=CC=3)C=3C=C(F)C(F)=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 NBXILYIJACTNDG-UHFFFAOYSA-N 0.000 claims 1
- UMOPRZIUHFFBEN-UHFFFAOYSA-N 5-(3-chlorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]thiophene-2-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3SC(=CC=3)C=3C=C(Cl)C=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 UMOPRZIUHFFBEN-UHFFFAOYSA-N 0.000 claims 1
- ZZVWDOFDAVXTIS-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]thiophene-2-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3SC(=CC=3)C=3C=CC(Cl)=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 ZZVWDOFDAVXTIS-UHFFFAOYSA-N 0.000 claims 1
- ZMNNARNHHOQVNW-UHFFFAOYSA-N 5-(4-fluorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]pyrazine-2-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3N=CC(=NC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 ZMNNARNHHOQVNW-UHFFFAOYSA-N 0.000 claims 1
- KDNFSIYGFOKCPG-UHFFFAOYSA-N 5-(4-fluorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]thiophene-2-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3SC(=CC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 KDNFSIYGFOKCPG-UHFFFAOYSA-N 0.000 claims 1
- BRTSOBBUFALQCT-UHFFFAOYSA-N 5-(4-methoxyphenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]thiophene-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=O)NC=2C=C3N=C(OC3=CC=2)N(C)C2CCN(C)CC2)S1 BRTSOBBUFALQCT-UHFFFAOYSA-N 0.000 claims 1
- OHEOLKHLDJYUCZ-UHFFFAOYSA-N 5-(5-chlorothiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(Cl)S1 OHEOLKHLDJYUCZ-UHFFFAOYSA-N 0.000 claims 1
- NUZWQKDXTFZYAX-UHFFFAOYSA-N 5-thiophen-3-ylthiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CSC=C1 NUZWQKDXTFZYAX-UHFFFAOYSA-N 0.000 claims 1
- ZUCVJIIRYGCSCT-UHFFFAOYSA-N 6-(4-fluorophenyl)-n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]pyridine-3-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3C=NC(=CC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 ZUCVJIIRYGCSCT-UHFFFAOYSA-N 0.000 claims 1
- ZALQSURZVFZOEZ-UHFFFAOYSA-N 6-(4-fluorophenyl)-n-[2-[methyl-[(1-methylpyrrolidin-3-yl)methyl]amino]-1,3-benzoxazol-5-yl]pyridine-3-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3C=NC(=CC=3)C=3C=CC(F)=CC=3)=CC=C2OC=1N(C)CC1CCN(C)C1 ZALQSURZVFZOEZ-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022714 Intestinal ulcer Diseases 0.000 claims 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N Methylcyclohexane Natural products CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000026758 coronary atherosclerosis Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 238000013016 damping Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- IKUCMRISMDTNMJ-UHFFFAOYSA-N n-[2-[(1-ethylpyrrolidin-3-yl)methyl-methylamino]-1,3-benzothiazol-6-yl]-4-(4-fluorophenyl)benzamide Chemical compound C1N(CC)CCC1CN(C)C(SC1=C2)=NC1=CC=C2NC(=O)C1=CC=C(C=2C=CC(F)=CC=2)C=C1 IKUCMRISMDTNMJ-UHFFFAOYSA-N 0.000 claims 1
- IUVLNRPQZDDSDE-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]-4-(2,4-dimethylphenyl)benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(C)C=C1C IUVLNRPQZDDSDE-UHFFFAOYSA-N 0.000 claims 1
- BSDHLTVXPGOMCF-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]-4-(2-methylphenyl)benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1C BSDHLTVXPGOMCF-UHFFFAOYSA-N 0.000 claims 1
- DXNJCJRPPBOPQU-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]-4-(4-fluoro-2-methylphenyl)benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(F)C=C1C DXNJCJRPPBOPQU-UHFFFAOYSA-N 0.000 claims 1
- MJCKIPNEXQMFHC-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzothiazol-6-yl]-4-(4-fluorophenyl)benzamide Chemical compound C1=C2SC(N(C)CCN(C)C)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(F)C=C1 MJCKIPNEXQMFHC-UHFFFAOYSA-N 0.000 claims 1
- KFWKWURGAWHHAU-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]-4-(2-methylpropoxy)benzamide Chemical compound C1=CC(OCC(C)C)=CC=C1C(=O)NC1=CC=C(OC(=N2)N(C)CCN(C)C)C2=C1 KFWKWURGAWHHAU-UHFFFAOYSA-N 0.000 claims 1
- VDTOLZSLLBILOP-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]-4-(4-fluorophenyl)benzamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=C(F)C=C1 VDTOLZSLLBILOP-UHFFFAOYSA-N 0.000 claims 1
- ZEZZQXWBFHJPDJ-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]-4-phenoxybenzamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 ZEZZQXWBFHJPDJ-UHFFFAOYSA-N 0.000 claims 1
- LSWXUIKQWAVDOQ-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]-4-phenylbenzamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 LSWXUIKQWAVDOQ-UHFFFAOYSA-N 0.000 claims 1
- PPALLMCFTWSXNB-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]-5-(4-fluorophenyl)pyrazine-2-carboxamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(N=C1)=CN=C1C1=CC=C(F)C=C1 PPALLMCFTWSXNB-UHFFFAOYSA-N 0.000 claims 1
- VOLWGJZOGHUICK-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-1,3-benzoxazol-5-yl]-6-(4-fluorophenyl)pyridine-3-carboxamide Chemical compound C=1C=C2OC(N(C)CCN(C)C)=NC2=CC=1NC(=O)C(C=N1)=CC=C1C1=CC=C(F)C=C1 VOLWGJZOGHUICK-UHFFFAOYSA-N 0.000 claims 1
- WQVXNSKERAVGRV-UHFFFAOYSA-N n-[2-[3-(diethylamino)propyl-methylamino]-1,3-benzothiazol-6-yl]-4-(4-fluorophenyl)benzamide Chemical compound C1=C2SC(N(C)CCCN(CC)CC)=NC2=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=C(F)C=C1 WQVXNSKERAVGRV-UHFFFAOYSA-N 0.000 claims 1
- QHVUCRLWQPIHQK-UHFFFAOYSA-N n-[2-[3-(diethylamino)propyl-methylamino]-1,3-benzoxazol-5-yl]-4-(4-fluorophenyl)benzamide Chemical compound C=1C=C2OC(N(C)CCCN(CC)CC)=NC2=CC=1NC(=O)C(C=C1)=CC=C1C1=CC=C(F)C=C1 QHVUCRLWQPIHQK-UHFFFAOYSA-N 0.000 claims 1
- BFPQQVBJAMWCQD-UHFFFAOYSA-N n-[2-[methyl-(1-methylpiperidin-3-yl)amino]-1,3-benzoxazol-5-yl]-4-phenylbenzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C=CC=CC=3)=CC=C2OC=1N(C)C1CCCN(C)C1 BFPQQVBJAMWCQD-UHFFFAOYSA-N 0.000 claims 1
- TWNYZFKMAOXGSF-UHFFFAOYSA-N n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]-3-phenoxybenzamide Chemical compound N=1C2=CC(NC(=O)C=3C=C(OC=4C=CC=CC=4)C=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 TWNYZFKMAOXGSF-UHFFFAOYSA-N 0.000 claims 1
- ZEMSUXTVIFPYDJ-UHFFFAOYSA-N n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]-4-phenylbenzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(=CC=3)C=3C=CC=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 ZEMSUXTVIFPYDJ-UHFFFAOYSA-N 0.000 claims 1
- GSXMLQGRFQUXJQ-UHFFFAOYSA-N n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]-5-(4-methylphenyl)thiophene-2-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3SC(=CC=3)C=3C=CC(C)=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 GSXMLQGRFQUXJQ-UHFFFAOYSA-N 0.000 claims 1
- NSKWYDIZTDYCJX-UHFFFAOYSA-N n-[2-[methyl-(1-methylpiperidin-4-yl)amino]-1,3-benzoxazol-5-yl]-5-phenylthiophene-2-carboxamide Chemical compound N=1C2=CC(NC(=O)C=3SC(=CC=3)C=3C=CC=CC=3)=CC=C2OC=1N(C)C1CCN(C)CC1 NSKWYDIZTDYCJX-UHFFFAOYSA-N 0.000 claims 1
- KYEKIAUYGKMCOK-UHFFFAOYSA-N n-[2-[methyl-[(1-methylpyrrolidin-3-yl)methyl]amino]-1,3-benzoxazol-5-yl]-4-phenoxybenzamide Chemical compound N=1C2=CC(NC(=O)C=3C=CC(OC=4C=CC=CC=4)=CC=3)=CC=C2OC=1N(C)CC1CCN(C)C1 KYEKIAUYGKMCOK-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000017497 prostate disease Diseases 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 230000036269 ulceration Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63711604P | 2004-12-17 | 2004-12-17 | |
| US60/637,116 | 2004-12-17 | ||
| PCT/US2005/045864 WO2006066173A2 (en) | 2004-12-17 | 2005-12-16 | Novel mch receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008524249A JP2008524249A (ja) | 2008-07-10 |
| JP2008524249A5 true JP2008524249A5 (enExample) | 2009-02-12 |
| JP4988591B2 JP4988591B2 (ja) | 2012-08-01 |
Family
ID=36481254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007546990A Expired - Fee Related JP4988591B2 (ja) | 2004-12-17 | 2005-12-16 | 新規なｍｃｈ受容体アンタゴニスト |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7838543B2 (enExample) |
| EP (1) | EP1828177B1 (enExample) |
| JP (1) | JP4988591B2 (enExample) |
| CN (1) | CN101072775A (enExample) |
| AT (1) | ATE404555T1 (enExample) |
| AU (1) | AU2005316313B2 (enExample) |
| BR (1) | BRPI0517425A (enExample) |
| CA (1) | CA2589678A1 (enExample) |
| DE (1) | DE602005009021D1 (enExample) |
| DK (1) | DK1828177T3 (enExample) |
| ES (1) | ES2312048T3 (enExample) |
| MX (1) | MX2007007226A (enExample) |
| PL (1) | PL1828177T3 (enExample) |
| PT (1) | PT1828177E (enExample) |
| SI (1) | SI1828177T1 (enExample) |
| WO (1) | WO2006066173A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2006038680A1 (ja) | 2004-10-01 | 2008-05-15 | 萬有製薬株式会社 | ２−アリールカルボキサミド−含窒素複素環化合物 |
| US7902356B2 (en) * | 2004-12-17 | 2011-03-08 | Eli Lilly And Company | Thiazolopyridinone derivates as MCH receptor antagonists |
| US8518950B2 (en) | 2005-01-25 | 2013-08-27 | Synta Pharmaceuticals Corp. | 2-amido pyrazines for inflammation and immune related uses |
| US8153813B2 (en) | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
| US20110306597A1 (en) | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| WO2010010435A2 (en) * | 2008-07-22 | 2010-01-28 | Glenmark Pharmaceutical S.A. | Fused oxazole and thiazole derivatives as trpms modulators |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| MX2012015102A (es) | 2010-07-06 | 2013-05-01 | Astrazeneca Ab | Agentes terapeuticos 976. |
| BR112013000925A2 (pt) | 2010-07-15 | 2020-12-01 | Bayer Intellectual Property Gmbh | compostos heterocíclicos como pesticidas |
| TW201305152A (zh) * | 2010-12-14 | 2013-02-01 | Shionogi & Co | 具有血管內皮脂肪酶抑制活性之苯并噻唑及吖苯并噻唑衍生物 |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
| SMT202400142T1 (it) | 2014-01-13 | 2024-05-14 | Aurigene Oncology Ltd | Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro |
| MX374526B (es) | 2015-06-22 | 2025-03-06 | Actelion Pharmaceuticals Ltd | Inhibidores de nadph oxidasa 4. |
| CN108024971A (zh) * | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的取代的氮杂化合物 |
| CN120267671A (zh) * | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| MX2020003666A (es) | 2017-10-31 | 2020-08-03 | Curis Inc | Compuestos y composiciones para el tratamiento de trastornos hematologicos. |
| CN109485620A (zh) * | 2018-12-26 | 2019-03-19 | 安徽工大化工科技有限公司 | 一种2-甲氧基-6-甲氧基苯并噻唑的制备方法 |
| AU2020274645A1 (en) * | 2019-05-14 | 2021-12-16 | Metabomed Ltd | ACSS2 inhibitors and methods of use thereof |
| US12178821B2 (en) | 2021-04-08 | 2024-12-31 | Curis, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756496A (en) | 1994-05-28 | 1998-05-26 | Smithkline Beecham P.L.C. | Amide derivatives having 5HT1D-antagonist activity |
| EP0971878B1 (en) | 1997-02-27 | 2008-03-26 | Takeda Pharmaceutical Company Limited | Amine compounds, their production and use as amyloid-beta production inhibitors |
| US7115750B1 (en) | 1999-09-20 | 2006-10-03 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonist |
| WO2001057008A1 (en) | 2000-02-07 | 2001-08-09 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| ATE479429T1 (de) * | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
| CA2408913A1 (en) * | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
| CA2428191A1 (en) * | 2000-11-07 | 2002-05-30 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| DE10139126A1 (de) * | 2001-08-09 | 2003-02-20 | Ciba Sc Pfersee Gmbh | Zusammensetzungen aus Polysiloxanen, Fluorpolymeren und Extendern |
| DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2468544A1 (en) * | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
| WO2004011440A1 (ja) * | 2002-07-30 | 2004-02-05 | Banyu Pharmaceutical Co., Ltd. | ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
| CA2509202A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
| KR100925307B1 (ko) * | 2005-03-09 | 2009-11-04 | 에프. 호프만-라 로슈 아게 | 항당뇨성 화합물로서 벤조티아졸, 티아졸로피리딘,벤조옥사졸 및 옥사졸로피리딘 유도체 |
-
2005
- 2005-12-16 CN CNA2005800418488A patent/CN101072775A/zh active Pending
- 2005-12-16 AU AU2005316313A patent/AU2005316313B2/en not_active Ceased
- 2005-12-16 PT PT05854552T patent/PT1828177E/pt unknown
- 2005-12-16 MX MX2007007226A patent/MX2007007226A/es active IP Right Grant
- 2005-12-16 AT AT05854552T patent/ATE404555T1/de active
- 2005-12-16 PL PL05854552T patent/PL1828177T3/pl unknown
- 2005-12-16 EP EP05854552A patent/EP1828177B1/en not_active Expired - Lifetime
- 2005-12-16 DE DE602005009021T patent/DE602005009021D1/de not_active Expired - Lifetime
- 2005-12-16 JP JP2007546990A patent/JP4988591B2/ja not_active Expired - Fee Related
- 2005-12-16 ES ES05854552T patent/ES2312048T3/es not_active Expired - Lifetime
- 2005-12-16 DK DK05854552T patent/DK1828177T3/da active
- 2005-12-16 US US11/719,576 patent/US7838543B2/en not_active Expired - Fee Related
- 2005-12-16 SI SI200530456T patent/SI1828177T1/sl unknown
- 2005-12-16 CA CA002589678A patent/CA2589678A1/en not_active Abandoned
- 2005-12-16 BR BRPI0517425-2A patent/BRPI0517425A/pt not_active IP Right Cessation
- 2005-12-16 WO PCT/US2005/045864 patent/WO2006066173A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10765676B2 (en) | Trk-inhibiting compound | |
| RU2412192C2 (ru) | Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2 | |
| ES2605388T3 (es) | Compuesto inhibidor de Trk | |
| RU2008100606A (ru) | Ингибиторы сфингозинкиназы | |
| JP2008524250A5 (enExample) | ||
| JP2006509801A5 (enExample) | ||
| ES2396741T3 (es) | Nuevo derivado de pirrol que tiene un grupo ureído y un grupo aminocarbonilo como sustituyentes | |
| TW200403223A (en) | Novel compounds | |
| CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| RU2007105970A (ru) | Пиперидиновые производные в качестве лигандов гистаминового из рецептора | |
| TW200404796A (en) | Nitrogen-containing compound | |
| RU2009116670A (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
| CN112204023A (zh) | 因子XIIa抑制剂 | |
| EP2455370A1 (en) | Pharmaceutical product containing lactam or benzene sulfonamide compound | |
| CA2473892A1 (en) | Novel quinoline derivatives | |
| JP2022553351A (ja) | Ｅｒｋ１およびｅｒｋ２の複素環式阻害剤の使用のための改善された方法、キット、組成物、ならびに投与レジメン | |
| NZ546012A (en) | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | |
| ES2441176T3 (es) | Nuevo compuesto que tiene un grupo 4-piridilalquiltio como sustituyente | |
| JP2014521618A (ja) | 置換複素環アザ誘導体 | |
| CN103228643A (zh) | 作为组胺h4受体配体的新颖苯并唑衍生物 | |
| RU2005137706A (ru) | Производное [1, 2, 4] триазоло [1, 5-а] пиримидин -2-илмочевины и его применение | |
| CA2615611A1 (en) | Indazole derivatives | |
| JP5815874B2 (ja) | Ｈｄｌコレステロール上昇剤としての３−ピリジンカルボン酸ヒドラジド | |
| CA2557789A1 (en) | Pyrazolyl indolyl derivatives as ppar activators | |
| TW202430511A (zh) | 咪唑衍生物 |